Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recMAGE-A3 + AS15 versus placebo after cystectomy in MAGE-A3-positive muscle-invasive bladder cancer
2010-024355-85Phase 2Completed
- Sponsor
- EAU Research Foundation
- Start
- May 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bladder cancer comparing recMAGE-A3 + AS15 ASCI with Placebo (2 arms). Primary endpoint: Disease-free survival. Started May 2011; status: completed.
02
Drugs
recMAGE-A3 recombinant protein
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2010-024355-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024355-85.